Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
Rhea-AI Summary
Traws Pharma (NASDAQ:TRAW) reported Q1 2026 results and business updates. The company closed a private financing of up to $60 million, including $10 million upfront, expected to fund operations and an influenza human challenge trial into Q1 2027.
Tivoxavir marboxil is progressing through a Phase 1 bridging study toward a once-monthly influenza prophylaxis challenge trial in the UK, while efforts continue to address an FDA clinical hold. Traws is also advancing a hantavirus antiviral candidate. Q1 2026 net loss was $7.1 million on revenue of $0.0 million, with cash of $3.1 million at March 31, 2026.
Positive
- Up to $60 million PIPE financing, including $10 million upfront
- Runway expected to extend operations into Q1 2027
- Funds expected to cover completion of influenza human challenge trial
- Advancement of TXM Phase 1 bridging study under open IND in Australia
- Planned single-dose influenza challenge trial of TXM at hVIVO in the UK
- G&A expense declined by $0.7 million year over year in Q1 2026
Negative
- FDA clinical hold on U.S. IND for TXM due to toxicology concerns
- Q1 2026 revenue was $0.0 million, down from $0.06 million in Q1 2025
- R&D expense increased to $4.9 million from $2.5 million year over year
- Q1 2026 net loss of $7.1 million versus prior-year net income
- Cash and cash equivalents of $3.1 million as of March 31, 2026
- Change in fair value of warrant liability was a $0.2 million expense in Q1 2026
News Market Reaction – TRAW
In the May 15 session, TRAW gained 15.34%, reflecting a significant positive market reaction. Argus tracked a peak move of +25.8% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Full-year 2025 earnings | Positive | -1.6% | Reported 2025 net income and highlighted $60M PIPE financing. |
| Nov 13 | Q3 2025 earnings | Negative | -17.3% | Q3 2025 net loss and ongoing development plus IP acquisition costs. |
| Aug 14 | Q2 2025 earnings | Negative | -1.2% | Q2 2025 net loss despite revenue and program progress updates. |
| May 15 | Q1 2025 earnings | Positive | -11.3% | Q1 2025 net income and promising TXM and ratutrelvir updates. |
| Mar 31 | Full-year 2024 earnings | Negative | -4.2% | Full-year 2024 showed a large net loss and rising expenses. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and results updates have typically been followed by negative price reactions, even when fundamentals or financing updates were constructive.
Across prior earnings and results updates since March 2025, Traws has repeatedly paired antiviral pipeline progress with challenging financials. Full-year 2024 showed a large net loss, while later quarters highlighted cash burn, net losses, and subsequent financing steps. By full-year 2025, the company reported net income and completed an up to $60M PIPE, yet shares still sold off. Today’s Q1 2026 report, featuring a return to net loss and reliance on recent financing to fund studies into Q1 2027, fits this pattern of cautious market responses to earnings updates.
Key Terms
private investment in a public equity (PIPE) financial
warrants financial
Phase 1 Bridging Study medical
clinical hold regulatory
human challenge trial medical
warrant liability financial
pre-funded warrants financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Private financing of up to
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent
Advancing clinical candidates for the treatment of hantavirus infections
NEWTOWN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today provided recent business highlights and reported financial results for the quarter ended March 31, 2026. The highlights include updates on the Company's lead program, tivoxavir marboxil (TXM), in development for influenza prophylaxis, and its hantavirus drug development efforts.
“Q1 2026 was a period of meaningful progress for Traws. The recently announced private financing of up to
Recent Highlights and Anticipated Milestones:
On April 15, 2026, TRAW announced an up to
The upfront gross proceeds and milestone-based warrants, along with the current cash and cash equivalents, are estimated to provide sufficient resources to fund company operations into Q1 2027 including completion of a human challenge trial to evaluate TXM as a once-monthly prophylactic agent for influenza prevention.
Investigational Programs:
Tivoxavir Marboxil (TXM, influenza):
Intended Indication and Market Potential: Potential as a best-in-class once-monthly prophylactic for seasonal flu and potential inclusion in pandemic preparedness initiatives,2,3 all-together, estimated to be a multi-billion-dollar opportunity.
Next Steps:
- Completion of Phase 1 Bridging Study – The ongoing Phase 1 Bridging Study, conducted under an open IND in Australia, is intended to evaluate if the compressed tablet formulation provides 28-days of coverage.
- MHRA Approval and Initiation of Challenge trial – Following completion of the Phase 1 Bridging Study and receipt of MHRA approval, TRAW will conduct a single-dose influenza virus challenge trial of TXM at hVIVO, a global leader in the conduct of human challenge studies for infectious diseases and respiratory viruses, in the UK.
- Efforts Ongoing to Resolve the Clinical Hold – FDA placed the U.S. IND for TXM on clinical hold due to concerns with the toxicology data package. The Company is preparing a comprehensive response, with the goal of resolving the hold and enabling initiation of global clinical studies by year end.
Hantavirus Program:
Intended Indication and Market Potential: Hantavirus, a rodent-borne negative-strand RNA virus that typically results in a 30
Next Steps: Traws plans to move rapidly to advance a clinical candidate for hantavirus treatment.
Financial Results:
Cash and cash equivalents: As of March 31, 2026, the Company had cash and cash equivalents of approximately
Revenue for the quarter ended March 31, 2026, was
Research and development (R&D) expense for the quarter ended March 31, 2026, totaled
General and administrative (G&A) expense for the quarter ended March 31, 2026, totaled
Change in fair value of warrant liability for the quarter ended March 31, 2026, was an expense of
Net Income (loss): The net loss for the quarter ended March 31, 2026 was
Shares Outstanding: Traws had 15,150,669 shares of common stock outstanding as of May 12, 2026.
About Tivoxavir Marboxil
Tivoxavir marboxil (TXM) is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dose prophylactic agent for seasonal influenza and treatment of pandemic/bird flu. It has shown potent in vitro activity against a range of influenza strains in preclinical studies, including a human isolate of the highly pathogenic avian flu H5N1 (bird flu). Consistent, positive preclinical data from three animal species indicate that a single dose of TXM demonstrated a therapeutic effect against H5N1 bird flu. Seasonal influenza represents an estimated multi-billion-dollar antiviral market opportunity, largely driven by global health organizations, practice guidelines and government tenders and inclusion in drug stock piling initiatives 2,3, with upside potential from potential pandemic flu outbreaks including H5N1 bird flu.
Source information
- Wall Street Journal. (2026, May 7). The 33-day 'Atlantic Odyssey' that turned into a hantavirus nightmare. The Wall Street Journal. https://www.wsj.com/world/the-33-day-atlantic-odyssey-that-turned-into-a-hantavirus-nightmare-ae8c7f48
- Per link
- Traws data on file
About Traws Pharma, Inc.
Traws Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. We are advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health including seasonal influenza and H5N1 bird flu, negative-strand RNA viruses including hantavirus and COVID-19/Long COVID. Lead program, tivoxavir marboxil, is in development as a once-monthly oral prophylactic agent for influenza prevention, with additional potential as a single-dose therapy for seasonal flu or H5N1 bird flu, targeting the influenza cap-dependent endonuclease (CEN).
For more information, please visit www.trawspharma.com and follow us on LinkedIn.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including the potential opportunity, market size, benefits, effectiveness, safety, and the clinical and regulatory plans for tivoxavir marboxil and ratutrelvir, as well as plans for its legacy programs. The Company has attempted to identify forward-looking statements by terminology including “believes”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, “may”, “could”, “might”, “will”, “should”, “preliminary”, “encouraging”, “approximately” or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the outcome of Traws’ IND filing with the FDA for tivoxavir marboxil, including the current FDA clinical hold; the success and timing of Traws’ clinical trials; Traws’ ability to identify and advance potential clinical candidates for the treatment of hantavirus infections, the potential efficacy of ratutrelvir for the treatment of COVID-19, including the potential to reduce the risk of COVID rebound and Long COVID; the potential for tivoxavir marboxil and ratutrelvir to gain market acceptance, if and when regulatory approval is obtained, or to become the new standard of care; Traws’ interactions with the FDA, BARDA and similar foreign regulators; collaborations; market conditions; regulatory requirements and pathways for approval; the ongoing need for improved therapy to reduce the frequency of clinical rebound and the concomitant risk for Long COVID; the extent of the spread and threat of pandemic flu including H5N1 bird flu; the Company’s cash projections; Traws’ ability to raise additional capital when needed; and those discussed under the heading “Risk Factors” in Traws’ filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law.
Traws Pharma Contact:
Charles Parker
Traws Pharma, Inc.
cparker@trawspharma.com
www.trawspharma.com
Investor Contact:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
| Traws Pharma, Inc. Condensed Consolidated Balance Sheets (unaudited) | |||||||
| March 31, | December 31, | ||||||
| 2026 | 2025 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 3,133,000 | $ | 3,820,000 | |||
| Tax incentive and other receivables | 1,687,000 | 3,794,000 | |||||
| Prepaid expenses and other assets | 845,000 | 365,000 | |||||
| Total current assets | 5,665,000 | 7,979,000 | |||||
| Property and equipment, net | 6,000 | 7,000 | |||||
| Intangible assets, net | 2,484,000 | 2,527,000 | |||||
| Other assets | 1,000 | 104,000 | |||||
| Total assets | $ | 8,156,000 | $ | 10,617,000 | |||
| Liabilities and stockholders’ deficit | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 7,665,000 | $ | 5,653,000 | |||
| Accrued expenses and other liabilities | 5,543,000 | 5,493,000 | |||||
| Total current liabilities | 13,208,000 | 11,146,000 | |||||
| Warrant liabilities | 259,000 | 100,000 | |||||
| Total liabilities | 13,467,000 | 11,246,000 | |||||
| Commitments and contingencies (Note 5) | |||||||
| Stockholders’ deficit: | |||||||
| Series C Preferred stock, | — | — | |||||
| Common stock, | 101,000 | 90,000 | |||||
| Additional paid-in capital | 641,681,000 | 639,259,000 | |||||
| Accumulated deficit | (647,091,000 | ) | (639,984,000 | ) | |||
| Accumulated other comprehensive (loss) income | (2,000 | ) | 6,000 | ||||
| Total stockholders’ deficit | (5,311,000 | ) | (629,000 | ) | |||
| Total liabilities and stockholders’ deficit | $ | 8,156,000 | $ | 10,617,000 | |||
| Traws Pharma, Inc. Condensed Consolidated Statements of Operations (unaudited) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Revenue | $ | — | $ | 57,000 | |||
| Operating expenses: | |||||||
| Research and development | 4,912,000 | 2,506,000 | |||||
| General and administrative | 2,034,000 | 2,754,000 | |||||
| Total operating expenses | 6,946,000 | 5,260,000 | |||||
| Loss from operations | (6,946,000 | ) | (5,203,000 | ) | |||
| Change in fair value of warrant liability | (159,000 | ) | 26,513,000 | ||||
| Other income, net | (2,000 | ) | 180,000 | ||||
| Net (loss) income | $ | (7,107,000 | ) | $ | 21,490,000 | ||
| Net (loss) income attributable to common stockholders, basic and diluted | $ | (5,692,000 | ) | $ | 15,083,000 | ||
| Weighted-average shares of common stock outstanding, basic | 10,640,625 | 6,965,927 | |||||
| Net (loss) income per share of common stock, basic | $ | (0.53 | ) | $ | 2.17 | ||
| Weighted-average shares of common stock outstanding, diluted | 10,640,625 | 7,215,125 | |||||
| Net (loss) income per share of common stock, diluted | $ | (0.53 | ) | $ | 2.09 | ||
| Net (loss) income attributable to Series C Preferred stockholders, basic and diluted | $ | (1,415,000 | ) | $ | 6,407,000 | ||
| Weighted-average shares of Series C Preferred outstanding, basic and diluted | 6,737 | 7,398 | |||||
| Net (loss) income per share of Series C Preferred, basic and diluted | $ | (210.03 | ) | $ | 866.04 | ||
